FFM
MRTX

Fairmount Funds Management’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

Fairmount Funds Management’s Portfolio MRTX Stock Details MRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-67,800
Closed -$11.6M – 21
2021
Q1 		$11.6M Buy
67,800
+7,300
+12% +$1.45M 4.9% 10
2020
Q4 		$13.3M Buy
60,500
+25,500
+73% +$5.51M 4.75% 11
2020
Q3 		$5.81M Buy
+35,000
New +$4.79M 2.46% 14

Other funds holding MRTX

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
AH
Aviva Holdings New Providence, Bahamas $20.5M AUM 117.01% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Fairmount Funds Management's MRTX Position: Q2 2021 in Review

Fairmount Funds Management sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q2 2021, closing a stake of 67,800 shares — an estimated $11.6M sold.

Fairmount Funds Management first reported a position in MRTX in Q3 2020 and held it in 3 quarters. The position peaked at $13.3M in Q4 2020. 245 funds tracked by Wall St. Rank hold MRTX as of Q2 2021.

  • Fairmount Funds Management reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q2 2021 after selling out during the quarter.
  • Fairmount Funds Management sold 67,800 Mirati Therapeutics, Inc. Common Stock shares in Q2 2021, an estimated $11.6M.
  • Fairmount Funds Management first reported a position in Mirati Therapeutics, Inc. Common Stock in Q3 2020 and held it in 3 quarters.
  • Fairmount Funds Management's Mirati Therapeutics, Inc. Common Stock position peaked at $13.3M in Q4 2020.
  • 245 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q2 2021.

Based on Fairmount Funds Management's 13F filing for Q2 2021, filed 13 Aug 2021.